title: What did we learn from the OPTIMAAL trial? What can we expect from VALIANT?
authors.forename: Kenneth
authors.initials: K
authors.lastname: Dickstein
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002216:Captopril / Q000627:therapeutic use*; D002423:Cause of Death; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D019808:Losartan / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D016032:Randomized Controlled Trials as Topic
chemical_list: D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002216:Captopril; D019808:Losartan